Molecular Devices (NASDAQ:MDCC)
Historical Stock Chart
From Jul 2019 to Jul 2024
Molecular Devices Introduces IMAP(R) Substrate Finder for
Tyrosine Kinases
SUNNYVALE, Calif., Sept. 13 /PRNewswire-FirstCall/ -- Molecular Devices
Corporation (NASDAQ:MDCC) today announced the introduction of its IMAP(R)
Substrate Finder for Tyrosine kinases, following the release of its initial
Substrate Finder for Serine/Threonine kinases in March. Together, they provide
substrates for the two categories of kinases that make up the human kinome. The
Substrate Finders for Tyrosine and Serine/Threonine kinases are based on
Molecular Devices' IMAP platform, which provides advanced tools for assay
development and high throughput screening (HTS) of kinases, one of the most
important target classes in drug discovery today. The development of successful
drugs that target kinases, such as Gleevac and Iressa which selectively target
cancer cells but leave healthy cells unharmed, is being aggressively pursued by
pharmaceutical and biotechnology companies, who are looking for quicker, easier
solutions for targeting kinase inhibitors.
Kinases are important because they play a critical role in the transmission of
signals, both within and between cells; any interference with their function
can lead to adverse effects. It is estimated that kinase malfunction
contributes to more than 400 diseases, including cancer, inflammatory disorders
like rheumatoid arthritis, diabetes, cardiovascular disease and neurological
disorders. One of the major roadblocks facing pharmaceutical and biotechnology
companies searching for potential drug targets for these diseases is finding a
suitable substrate. The IMAP Substrate Finder accelerates the difficult task of
finding new substrates by providing a quick, sensitive, yet inexpensive method
to screen dozens of substrates in a couple of hours versus days or weeks.
"Kinase inhibitors are important drug targets that are screened at all major
pharmaceutical companies. They represent a new generation of drugs that target
the underlying molecular processes of the cell and are in a position to
radically change the future treatments for cancer and other diseases," stated
Stephen Oldfield, Ph.D. and Vice President of Worldwide Marketing at Molecular
Devices. "Molecular Devices' IMAP technology continues to meet the growing
demands of high throughput screening, with its stable signal, precision,
inherent flexibility and the ease in which it is incorporated into all kinase
screening. It is rapidly becoming the preferred assay to screen for kinase
activity. With the IMAP Substrate Finder, the pace of assay development and
screening for unique or proprietary kinases is accelerated with the same ease
of miniaturization and low cost-per-well that IMAP users have come to expect."
Molecular Devices Corporation is a leading supplier of high-performance
bioanalytical measurement systems that accelerate and improve drug discovery
and other life sciences research. The Company's systems and consumables enable
pharmaceutical and biotechnology companies to leverage advances in genomics,
proteomics and combinatorial chemistry by facilitating the high- throughput and
cost-effective identification and evaluation of drug candidates. The Company's
solutions are based on its advanced core technologies that integrate its
expertise in engineering, molecular and cell biology and chemistry. Molecular
Devices enables its customers to improve research productivity and
effectiveness, which ultimately accelerates the complex process of discovering
and developing new drugs.
This press release contains "forward-looking" statements, including statements
related to the prospects for or potential customer use of the IMAPÒ Substrate
Finder. Any statements contained in this press release that are not statements
of historical fact may be deemed to be forward-looking statements. Words such
as "believes," "anticipates," "plans," "expects," "will," and similar
expressions are intended to identify forward-looking statements. There are a
number of important factors that could cause the results of Molecular Devices
Corporation to differ materially from those indicated by these forward-looking
statements, including, among others, risks related to the development of new
products and other risks detailed from time to time in the Company's SEC
reports, including its Annual Report on Form 10-K for the year ended December
31, 2003, as amended, and its Quarterly Report on Form 10-Q for the quarter
ended June 30, 2004. Molecular Devices Corporation does not undertake any
obligation to update forward-looking statements.
DATASOURCE: Molecular Devices Corporation
CONTACT: Tim Harkness of Molecular Devices Corporation, +1-408-747-3533
Web site: http://www.moleculardevices.com/